Home  |  Contact

UniProtKB/Swiss-Prot P13569: Variant p.Cys225Arg

Cystic fibrosis transmembrane conductance regulator
Gene: CFTR
Variant information

Variant position:  225
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  US
The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change:  From Cysteine (C) to Arginine (R) at position 225 (C225R, p.Cys225Arg).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from medium size and polar (C) to large size and basic (R)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  -3
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description:  In CF; unknown pathological significance.
Any additional useful information about the variant.

Other resources:  
Links to websites of interest for the variant.



Sequence information

Variant position:  225
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  1480
The length of the canonical sequence.

Location on the sequence:   PLQVALLMGLIWELLQASAF  C GLGFLIVLALFQAGLGRMMM
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         PLQVALLMGLIWELLQASAFCGLGFLIVLALFQAGLGRMMM

Gorilla                       PLQVALLMGLIWELLQASAFCGLGFLIVLALFQAGLGRMMM

                              PLQVTLLMGLLWDLLQASAFCGLAFLIVLALVQAGLGRMIM

Rhesus macaque                PLQVALLMGLIWELLQASAFCGLGFLIVLALFQAGLGRMMM

Chimpanzee                    PLQVALLMGLIWELLQASAFCGLGFLIVLALFQAGLGRMMM

Mouse                         PLQVTLLMGLLWDLLQFSAFCGLGLLIILVIFQAILGKMMV

Rat                           PLQVVLLMGLLWDLLQFSAFCGLGLLIVLVIFQAILGKMMV

Pig                           PLQVTLLMGLLWELLQASAFCGLAFLVVLALFQAGLGKMMM

Bovine                        PLQVTLLMGLLWELLQAFTFCGLAFLIVLALLQAGLGKMMM

Rabbit                        PLQVTLLMGLLWELLQASAFCGLAFLIVLALVQAGLGRMMM

Sheep                         PLQVTLLMGLLWDLLQAFTFCGLAFLVVLALLQAGLGKMMM

Horse                         PLQVTLLMGLLWDLLQASAFCGLAFLIVLALFQAGLGRMMM

Xenopus laevis                PLQVLLLMGLLWDLLQASAFCGLGFLIILSLFQARLGRMMM

Zebrafish                     PLQCILCTGLIWELIDVNSFCALAAISLLGVLQAFLSHKMG

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 1 – 1480 Cystic fibrosis transmembrane conductance regulator
Transmembrane 223 – 243 Helical; Name=4
Domain 81 – 365 ABC transmembrane type-1 1
Helix 222 – 244


Literature citations

Molecular characterization of cystic fibrosis: 16 novel mutations identified by analysis of the whole cystic fibrosis conductance transmembrane regulator (CFTR) coding regions and splice site junctions.
Fanen P.; Ghanem N.; Vidaud M.; Besmond C.; Martin J.; Costes B.; Plassa F.; Goossens M.;
Genomics 13:770-776(1992)
Cited for: VARIANTS VAL-44; MET-470; VAL-506; CYS-508; ALA-576; CYS-668; PHE-997; THR-1027 AND LEU-1162; VARIANTS CF GLY-44; ARG-178; ARG-225; TRP-334; PHE-508 DEL; 542-GLY--LEU-1480 DEL; ASP-551; ILE-562; ARG-628; 710-LYS--LEU-1480 DEL; 846-TRP--LEU-1480 DEL; CYS-913; 1063-TRP--LEU-1480 DEL; CYS-1066; 1092-TYR--LEU-1480 DEL; 1162-ARG--LEU-1480 DEL; GLU-1200; 1282-TRP--LEU-1480 DEL AND LYS-1303;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.